English system diabetes switch news about members investors news news archive cellnovo lists on euronext paris first e-connected insulin micro-pump raises funds to accelerate expansion Paris – 10 July 2015 – EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs , today celebrated the listing of Cellnovo Group (Cellnovo), a medical devices company that has developed and markets the first connected insulin micro-pump for managing diabetes. The company was admitted on the Compartment C of Euronext Paris. Based in France and the United Kingdom, Cellnovo has developed and markets the first connected all-in-one diabetes management that helps make life easier for diabetics. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo aims to improve the quality of life of patients with type 1 diabetes and more generally all insulin dependent people, by using its technology to minimise the constraints and risks associated with this illness. Cellnovo (ticker code: CLNV) was listed through the admission to trading on 10 July 2015 of the 10.683.873 ordinary shares making up its equity, including 2.969.557 new shares issued through a Global Offering . The admission and issue price of Cellnovo shares was set at €10.63 per share. Market capitalisation was around €113.569.570 on the day of listing. The total amount raised was €31.566.391 million. Eric Beard, Chairman and CEO of Cellnovo, said: «We are pleased to welcome new top-quality investors alongside our historical shareholders and Air Liquide Venture Capital. We thank each of them for putting their trust in our disruptive insulin pump technology. Now we look forward to working with them towards bringing the company to a next level, through the scale-up of our production capabilities and the speed-up of our commercial expansion.» Albert Ganyushin, Head of International Listings , Euronext added: «We are delighted to welcome Cellnovo on Euronext Paris. Cellnovo’s innovative solution combining e-health and a connected micro-pump for diabetes patients provides a glimpse into the future of healthcare. We are delighted that this innovative company, founded in the United Kingdom, turned to our markets to finance the next stage of its growth. Cellnovo's listing highlights our ability to attract leading European life science companies to our market, the growing international reputation of our franchise and Euronext's continued momentum in the current market conditions. About Cellnovo Group An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. With Cellnovo’s device, certain aspects of diabetes management still require an action from the patient (blood glucose monitoring and injection of insulin just before meals).This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time. Cellnovo aims to improve the quality of life of patients with type 1 diabetes and more generally all people living with insulin dependency, by using its technology to minimise the constraints and risks associated with this illness. The current version of the system has already received CE Marking, is reimbursed in most countries and is already being marketed in France and the United Kingdom. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to cope with the expected high level of demand. The insulin pump market is currently estimated to be worth around 2.2 billion dollars, and has substantial potential given that only 17% of the 3.5 million people with type 1 diabetes (in the US/Canada and main European countries) currently use a pump. Based in France and the United Kingdom, Cellnovo has a 75-strong workforce. About EnterNext Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalisations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs. EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level. About Euronext Euronext is the primary exchange in the euro zone with over 1,300 issuers worth €3.2 trillion in market capitalisation, an unmatched blue-chip franchise consisting of 24 issuers in the EURO STOXX 50® benchmark and a strong, diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds (ETFs), Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs’ access to capital markets. Disclaimer This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use. Contacts – Euronext: Vanessa Stephan: +33 1 70 48 24 42; vstephan@euronext.com Aïchata Tandjigora: +33 1 70 48 24 43; atandjigora@euronext.com Investor relations / Media: Sophie Baratte investors@cellnovo.com Antoine Denry: +33 (0) 1 44 71 94 95 Nicolas Merigeau: +33 (0) 1 44 71 94 98 cellnovo@newcap.fr © 2015 10.07.15 Cellnovo lists on Euronext Paris 19.06.15 Cellnovo Starts the Expansion of its Distribution Network 17.06.15 Cellnovo Joins the Diabeloop© Artificial Pancreas Development Programme 11.06.14 cellnovo wins BIOVISION investor conference award 22.04.14 cellnovo strengthens senior management team 05.02.14 cellnovo launches first mobile diabetes management system News Archive Switch to Cellnovo Leadership About privacy policy info@cellnovo.com +44 (0) 203 058 1250 © copyright 2012 Cellnovo